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Background. Quantitative human immunodeficiency virus (HIV) RNA load testing surpasses CD4 cell count
and clinical monitoring in detecting antiretroviral therapy (ART) failure; however, its cost can be prohibitive.
Recently, the use of pooling strategies with a clinically appropriate viral load threshold was shown to be accurate and
efficient for monitoring when the prevalence of virologic failure is low.
Methods. We used laboratory request form information to identify specimens with a low pretest probability of
virologic failure. Patients aged>15 years who were receiving first-line ART had individual viral load results available
were eligible. Blood plasma, dried blood spots, and dried plasma spots were evaluated. Two pooling strategies were
compared: minipools of 5 samples and a 10310 matrix platform (liquid plasma specimens only). A deconvolution
algorithm was used to identify specimens(s) with detectable viral loads.
Results. The virologic failure rate in the study sample was ,10%. Specimens included were liquid plasma
specimens tested in minipools(n 5 400), of which 300 were available for testing by matrix, and specimens tested
with minipools only: dried blood spots (n 5 100) and dried plasma spots (n 5 185). Pooling methods resulted in
30.5%–60% fewer HIV RNA tests required to screen the study sample. For plasma pooling, the matrix strategy had
the better efficiency, but minipools of 5 dried blood spotshad the best efficiency overall and were accurate at a.95%
negative predictive value with minimal technical requirements.
Conclusions. In resource-constrained settings, a combination of preselection of patients with low pretest
probability of virologic failure and pooled testing can reduce the cost of virologic monitoring without
compromising accuracy.
More than 5.5 million people in South Africa are in-
fected with human immunodeficiency virus (HIV), and
the prevalence is almost 17% among adults 15–49 years
of age[1]. Approximately one million of these in-
dividuals are currently receiving antiretroviral therapy
(ART), a number expected to increase as HIV disease
progression continues and as recommendations change
to start ART at higher CD4 cell counts[2]. ART has
dramatically reduced the burden of disease in the
Western Cape Province of South Africa[3]. For example,
access to ART has reduced the 6-month mortality
among HIV-infected individuals at 1 health center from
12.7% to 6.6%[3], and early diagnosis and treatment
reduced deaths in children by 76% at 2 centers[4]. Al-
though access to ART saves many lives, in South Africa
and elsewhere, it means massive expenditure for medi-
cation, clinical services, and laboratory monitoring.
Even though HIV load (VL) testing in the South African
public sector costs only US$40 per test (including labor
reagents and instrumentation costs), it remains rela-
tively expensive. However, VL testing has been shown to
be superior to CD4 cell count and clinical monitoring
for detecting ART failure[5–9]. In the absence of VL
monitoring, patients who have virological response to
ART may be unnecessarily switched to second-line
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therapy, and other patients retained on a failing first-line ART
regimen, which is composed of a nonnucleoside reverse-
transcriptase inhibitor (NNRTI) and 2 nucleoside reverse-tran-
scriptase inhibitors (NRTIs), in many resource-limited settings,
resulting in clinical deterioration and the accumulation of re-
sistance mutations. Indeed, when CD4 cell count and/or clinical
monitoring is used to identify ART failure, a greater percentage
of patients harbor both thymidine analogue mutations and
mutations such as K65R[10] than when VL monitoring is
used[11–14]. Thus, unrecognized failure could compromise
second-line ART, which in South Africa currently is composed of
ritonavir-boosted lopinavir plus 2 NRTIs, lamivudine, and either
tenofovir or zidovudine[15]. Although VL testing is extremely
valuable for monitoring patients receiving ART, it is unafford-
able in many countries that rely on inadequate patient moni-
toring with CD4 cell count and clinical criteria alone.
Strategies that reduce the cost of VL monitoring could
therefore increase access to VL monitoring. One such strategy is
the pooled testing of samples.
Pooled HIV RNA testing is the performance of HIV RNA
testing of pools made from multiple patient specimens, which is
efficient in screening blood donors[16] and for diagnosing acute
HIV infection[17–19]. Recently, pooled testing using a clinically
appropriate VL threshold has been shown to be an accurate and
efficient method for detecting virological failure in patients re-
ceiving ART[20]. The efficiency of a pooling strategy is, how-
ever, largely dependent on the pretest probability of ART
failure[21]. If failure in a population is .25%, the saving ach-
ieved through pooling decreases to,30%[21]. Therefore, in this
study we first evaluated how basic demographic information
recorded on standard laboratory request forms can be used to
select patients receiving ART who have a low probability of
virologic failure (,10%) and then compared minipool and
matrix strategies to reduce costs of virologic monitoring. To
maximize the usefulness of procedures in resource-limited set-
tings, we also evaluated minipools using dried blood spots
(DBS) and dried plasma spots (DPS).
MATERIALS AND METHODS
Study Population and Screening Criteria
The study was approved by the Stellenbosch University Com-
mittee for Human Research. To determine selection criteria for
identifying a study population with low (,10%) probability of
having virologic failure and thus eligible for pooled VL testing, we
performed a retrospective, descriptive analysis with use of in-
formation entered on routine laboratory request forms by health
care providers. Four representative weeks (ie, excluding holiday
seasons) from August 2008 through August 2009 were randomly
selected. All VL tests performed during these weeks by the routine
virology laboratory at the National Health Laboratory Service in
Tygerberg, South Africa, were included, and information
entered on the routine laboratory request forms was collected.
The VL threshold for defining ART failure throughout this
investigation was defined a priori as VL .1000 HIV RNA
copies/mL, which is the current threshold for virologic failure
in South Africa[15]. The simplest combination of variables was
selected that would predict a low pretest probability of having
virologic failure. The criteria, thus identified, were applied to
prospectively select patient specimens for all subsequent
pooled VL testing, excluding only specimens with insufficient
specimen volumes remaining after individual VL testing had
been performed.
Pooled Testing of Liquid Blood Plasma Specimens
The effectiveness and accuracy of routinely performed in-
dividual VL testing were compared with those of pooled VL
testing using blood plasma specimens. Specimens stored at
280C were selected according to the previously established
criteria. Two different pooling strategies were used: minipools of
5 samples and 10310 matrix pools. At a VL threshold of 1000
HIV RNA copies/mL for defining ART failure for an individual
specimen, the VL threshold applicable to pools is 200 HIV RNA
copies/mL for the minipool platform and 100 HIV RNA copies/
mL for the matrices. Times required to constitute the pools were
recorded. Resolution of pools to identify which samples were
above the virologic threshold was done using a previously
published search-and-test algorithm, implemented in the Mea-
surement Enhanced Pooling Assay Calculator of the University
of California, San Diego, available at http://mepac.ucsd.edu/
[20]. Briefly, for matrix pools this algorithm uses results of
horizontal and vertical pools to resolve some individual speci-
mens and directs one to test the remaining individual specimens
in the most efficient order, thereby reducing the number of tests
needed. For minipools, this algorithm subtracts the contribution
of sequentially tested individual samples from the pooled VL
until the pool is resolved below the defined level of virologic
failure, at which stage no further testing of individual specimens
is needed. For each of these strategies, we calculated the negative
predictive value and number of assays performed relative to
testing each sample individually (ie, efficiency and the potential
cost differential between individual and pooled VL testing
strategies).
Pooled Testing with DBS and DPS
Pooling of specimens was also evaluated in the minipool
platform using DBS (n 5 100) and DPS (n 5 185). DBS and
DPS were prepared from specimens meeting the aforemen-
tioned criteria and that had individual VL test results from
liquid plasma specimens. Spots were dried overnight, and
cards were kept in plastic bags with desiccants at room tem-
perature until tested within 3 days after preparation. Only
minipools of 5 were constituted, as previously described for
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liquid plasma[20–21]. The following experiments were con-
ducted: one DBS per patient was eluted in 3 mL lysis buffer,
and the pool VL results were examined at thresholds of 133,
200, 400, and 1000 HIV RNA copies/mL to define a positive
pool; 2 DBS per patient eluted in 10 mL lysis buffer were
examined at thresholds of 200 and 300 copies/mL; and one
DPS per patient eluted in 3 mL lysis buffer was examined at
thresholds of 133 and 200 copies/mL. The threshold of 200
was chosen on the basis of this corresponding to an individual
VL of 1000 HIV RNA copies/mL when 5 patient specimens are
pooled, and 133 was chosen on the basis of correcting for the
amount of eluant absorbed by the DBS (1mL of the original
3mL was absorbed). The other thresholds were multiples
of 200.
Figure 1. Retrospective evaluation of laboratory form information to identify patient specimens suitable for pooled viral load testing. The
strategy used to select demographic information on routine laboratory request forms that can be used as criteria to identify specimens with a low pretest
probability of having HIV RNA loads.1,000 copies/mL (ie, virologic failure as defined in this study). Specimens were excluded from pooled testing on the
basis of the form containing no antiretroviral therapy information, the inclusion of a protease inhibitor (PI) in the regimen, or the patient being,15 years
of age. Specimens that were eligible for pooled viral load testing were from patients at least 15 years of age who were receiving a nonnucleoside
reverse-transcriptase inhibitor regimen.
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VL Testing and Pooling Algorithm
All individual and pooled VL testing was done using the
NucliSENS easyQ, version 2 system (bioMerieux) with a lower
level of HIV RNA detection of 25 HIV RNA copies/mL for input
volumes of 1 mL of plasma.
RESULTS
Establishing Screening Criteria for Patients with Low
Probability of Virologic Failure
The process of identifying suitable selection criteria for patients
with a low probability of failure is shown in Figure 1. The
2 criteria needed to identify a target population with virologic
failure prevalence ,10% on individual testing were age >15
years and treatment with a first-line (NNRTI-based) regimen.
The evaluated retrospective sample had a failure rate of 14.2%
before and 8.7% after applying these criteria (see Figure 1). The
characteristics of the patient specimens included in the pro-
spective study of pooled testing are shown in Table 1.
Pooled Testing Using Blood Plasma
A total of 400 stored specimens were available to be tested with
the minipool—and 300 of these with the 10310matrix strategy.
Specimens were tested in 80 minipools, and the mean time re-
quired to constitute 20 minipools (100 individual specimens)
was 35.5 min. VL test results of 3 minipools were invalid; thus,
all those 15 individual specimens required individual testing. In
total, only 69.5% of the 400 tests that would have been needed
for individual testing were used in the minipool strategy. This
30.5% reduction of tests used would have resulted in a reagent
cost savings of US$1220 per 100 specimens, based on the cost
for one VL test of US$40 (ZAR 300).
For the 103 10 matrix strategy, 300 patients were tested in 3
matrices. The mean time to constitute one matrix consisting of
100 individual samples was 45 min, 10 min more than pre-
paring minipools for the same number of specimens. Using the
Measurement Enhanced Pooling Assay Calculator for decon-
volution, only 59% of the tests needed for individual testing
would have to be performed, resulting in a reagent savings of
US$1640 per 100 specimens. The negative predictive value for
both methods was .95% (Table 2).
Pooled Viral Load Testing Using DBS and DPS
When one DBS was eluted into 3 mL of lysis buffer, pooling
efficiencies as compared with individual testing ranged from
210% to 20% depending on the VL threshold used to define
a positive pool (133, 200, 400, and 1000 HIV RNA copies/mL).
When 2 DBS were eluted in 10 mL of lysis buffer, pooling effi-
ciencies were 5% and 25% for pool VL thresholds of 200 and 400
HIV RNA copies/mL, respectively (Table 3). The slight increase
in efficiency was, however, offset by a decrease in negative pre-
dictive value when using the larger eluant volume (Table 3). The
efficiency of DPS pooling, however, remained similar (57% vs
60%) for pool thresholds of 133 and 200 HIV RNA copies/mL.
The associated increase in positive predictive value from 92% to
100% was attributable to a single pool with a VL of 190 copies/
mL testing false-positive at the 133 HIV RNA copies threshold
but not at 200. Only one DPS pool tested false-negative, and this
pool had 1 specimen with a low VL of 1200 copies/mL (Table 3).
DISCUSSION
The long-term clinical success of ART depends on regular VL
monitoring inpatients, and the long-term sustainability of ART
programs in resource-constrained countries will require the
availability of VL testing. Although novel approaches, from
point-of-care VL assays [22] to alternatives to the commercially
available laboratory-based VL assays, are urgently needed [23],
pooled testing could be implemented rapidly to substantially
reduce the reagent costs of VL testing and thereby make VL
testing more affordable. Currently available commercial assays
require specialized equipment, well-equipped laboratories, and
skilled staff; therefore, these assays are only viable in a few
centralized laboratories, which could, nevertheless, improve
their use of expensive resources through innovative but accurate
testing strategies.
In our study, the 10310 matrix pool strategy had a higher
efficiency than the 5-specimen minipool strategy (41% re-
duction in VL tests needed, compared with 30.5%), most likely
because of 3 minipools pools with invalid VL tests. However, the
minipool strategy was easier in practice, in both time and ex-
pertise required to constitute and deconvolute the pools.
Table 1. Characteristics of Specimens Included in Different Pooling Strategies
Pooling Strategy
(individual
specimens tested)
Plasma Minipool
(n 5 400)
Plasma
Matrix Pool
(n 5 300)
Dried Blood
Spot Minipool
(n 5 100)
Dried Plasma
Spot Minipool
(n 5 200)
Mean log10Viral Load (VL) 2.88 2.88 2.94 2.39
VL range (copies/mL) 55–470,000 55–470,000 53–94,000 51–260,000
VL . 1000 9.50% 11.00% 9.00% 7.57%
50 , VL , 1000 14.25% 16.67% 11.00% 8.65%
VL . 50 23.75% 27.67% 20.00% 16.21%
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Moreover, the 10310 matrix requires 100 samples to be avail-
able before any can be tested, whereas minipools require mul-
tiples of 5 specimens only, which could be preferable in terms of
turnaround time enabling rapid clinical decision making. Fur-
thermore, due to the difficulty of correctly constituting the
10310 matrix, it may require experienced laboratory personnel,
which could greatly limit its use in resource-constrained settings.
We also explored the use of DBS and DPS for pooled VL
testing. Other studies [24–29], one of them using the same
platform for VL testing [27], found similar results with DBS
having a mean VL lower than in liquid plasma; however, this will
most likely depend on the proportion of patients who have
virological failure, where cell-associated HIV RNA may con-
tribute more or less to the measured VL in a DBS, compared
with that in liquid plasma. This could be especially relevant
when DBS are pooled, as a larger volume of blood, containing
more cells, is tested compared with individual DBS VL testing.
Furthermore, the use of DBS is complicated by the variable
plasma fraction due to differences in hematocrit between pa-
tients. The combination of these factors and the high variability
could result in a falsely high VL when compared with individual
plasma testing and could explain the observed poorer specificity
and efficiency of pooled DBS testing. In contrast, pooled testing
of DPS yielded less variability and excellent efficiency and ac-
curacy at both pool thresholds of 133 copies and 200 HIV RNA
copies/mL. The only measured difference between these 2
thresholds was due to one negative pool that had a VL result of
190 HIV RNA copies/mL and was thus false-positive at 133
copies and true-negative at the 200 HIV RNA copies/mL
threshold. The one pool that tested false-negative had a speci-
men with a relatively low VL of 1,200 HIV RNA copies/milliliter.
The study sample evaluated with DPS did have a lower preva-
lence of virologic failure than the DBS sample (7.6% vs 9%).
However, it is unlikely that this alone would account for the
difference in observed efficiency between the methods, which
most likely should be ascribed to the absence of cellular HIV
RNA and less variability in the plasma, compared with whole
blood input. In addition, the observed efficiency difference
could be due to effects of inhibitory substances such as hemo-
globin in DBS but not in DPS. The excellent efficiency of DPS
pooling of about 60% could have resulted in cost savings of
about US$2400 per 100 specimens screened for virologic failure.
Table 2. Comparison of Minipools and Matrix Pools
Method
Prevalence of Failure
(.1,000 RNA copies/mL)
Negative Predictive
Value
Relative Efficiency
(reduction in
tests needed)
Cost Savings per
100 Specimens
(US$40 per viral load test)
3 matrices (n 5 300 specimens) 11% 98% 41% US$1,640
80 minipools (n 5 400 specimens) 9.50% 100% 30.5% US$1,220
Table 3. Efficiency and Accuracy of Minipool Viral Load Testing of Dried Blood Spots (DBS) and Dried Plasma Spots (DPS)
Summary Results At Pool Threshold (HIV RNA copies/mL)
DBS
1 DBS in 3ml (20 minipools of 5) 133 200 400 1000
Efficiency –10.00% –5.00% 5.00% 20.00%
Sensitivity 100.00% 100.00% 87.50% 75.00%
Specificity 20.00% 30.00% 40.00% 60.00%
Positive Predictive Value 50.00% 53.33% 53.85% 60.00%
Negative Predictive Value 100.00% 100.00% 80.00% 75.00%
2 DBS in 10mL(20 minipools of 5) – 200 400 –
Efficiency – 5.00% 25.00% –
Sensitivity – 100.00% 88.89% –
Specificity – 45.45% 72.73% –
Positive Predictive Value – 60.00% 72.73% –
Negative Predictive Value – 100.00% 88.89% –
DPS
1 DPS in 3 mL(37 minipools of 5) 133 200 –
Efficiency 57.30% 60.00% –
Sensitivity 92.31% 92.31% –
Specificity 95.83% 100.00% –
Positive Predictive Value 92.31% 100.00% –
Negative Predictive Value 95.83% 96.00% –
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The efficiencies for the liquid plasma minipool and matrix
pooling experiments were lower than previously reported [20],
where efficiencies for both strategies were above 50%. This could
be due to the higher mean VL in our sample (log10VL of 2.88 vs.
2.33 copies/mL) or in the case of the minipools, the 3 pools that
had invalid VL test results. For DPS pooling, however, the ef-
ficiency was 60% and therefore comparable to this previous
study. It is unlikely that the low prevalence of virologic failure
(7.6%) of the sample of specimens included in the DPS exper-
iment alone accounts for the better efficiency of DPS pooling
than liquid plasma pooling. The improvement observed with
DPS pooling probably results from the lower plasma volume
input in the DPS and therefore higher detection limit, which
could contribute to the observed lower false-positive rate
(0%–2.7% for DPS minipools vs. 16.25% for liquid plasma
minipools). This increased the overall efficiency, as fewer false-
positive pools needed deconvolution compared with liquid
plasma pooling using minipools.
One limitation of this study was that it was retrospective, in
the sense that we compared the results of pooled VL testing of
stored specimens to results of previously conducted routine in-
dividual VL testing: Specimens were thus exposed to one cycle of
freezing and thawing between individual testing and pooled
testing. Another limitation was that we did not compare the
DBS- or DPS-pooled VL to DBS or DPS specimens tested in-
dividually but, rather, to known (previously tested) liquid plasma
VL. These will need to be evaluated in a future prospective study.
Furthermore the cost-efficiency of pooling is dependent on the
variable costs of labor, reagents, and equipment and the possible
different health impacts of VL monitoring in various settings,
depending on the ART regimens that are available.
In this study, simple laboratory request form information was
found to be valuable in identifying patients who have a low
probability of virological failure. This could be crucial for
identifying which specimens are suited for pooled or in-
dividualized testing. We have also shown that in a resource-
constrained setting, a combination of preselecting patients with
low pretest probability of virologic ART failure followed by
pooled VL testing can reduce costs without compromising ac-
curacy, and that DPS minipooling was the most efficient
method. Taken together, this could be very valuable when
considering a centralized laboratory equipped with automated
liquid-handling systems for preparing pools and software to
assist with the deconvolution of positive pools. This would allow
an increase in the number of patients tested without needing
more VL tests, testing equipment, or staff.
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